68Ga–Prostate-Specific Membrane Antigen-11 PET/CT
Tóm tắt
Glioblastoma multiforme (GBM) is the most common and most aggressive primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of recurrences occur at the surgical margins. Currently, limited data are available in the literature on the possible use of 68Ga–prostate-specific membrane antigen (PSMA-11) for diagnosis of recurrence in GBM patients. The aim was to assess the feasibility and potential of 68Ga-PSMA-11 PET/CT as a diagnostic procedure in patients with histologically confirmed of GBM and suspected recurrent disease on MRI.
No radiopharmaceutical-related adverse events were noted. Characterization of recurrent disease with MRI included T2-weighted fast spin-echo images, fluid-attenuated inversion recovery and diffusion-weighted imaging sequences, and gadolinium enhanced T1-weighted images. Visual interpretation of PET showed increased accumulation of 68Ga-PSMA-11 in recurrent lesion detected by T1 contrast enhanced and diffusion-weighted imaging images in all patients with a median SUVmax of the tumor of 6.5 and an SUVmean of 3.5. The median tumor-to-background brain ratio and tumor-to-liver ratio obtained from 68Ga-PSMA-11 PET/CT were 96.7 and 0.8, respectively.
The extremely low background uptake in normal brain tissue and consequently high tumor-to-brain ratio make 68Ga-PSMA-11 PET/CT highly promising for diagnosis of recurrent disease in GBM patients. Although PSMA expression in recurrent GBM also opens a potential way for targeted peptide therapy with α/β-emitters as well as for prediction of treatment with antiangiogenic agents, the low tumor-to-liver ratio observed in the majority of patients in this study suggests a limited role of radiolabeled PSMA ligands for targeted radionuclide therapy of recurrent GBM.
Từ khóa
Tài liệu tham khảo
2014, Emerging treatment strategies for glioblastoma multiforme, EMBO Mol Med, 6, 1359, 10.15252/emmm.201302627
1998, “Facilitated” amino acid transport is upregulated in brain tumors, J Cereb Blood Flow Metab, 18, 500, 10.1097/00004647-199805000-00005
2008, The role of 18F-FLT in cancer imaging: does it really reflect proliferation?, Eur J Nucl Med Mol Imaging, 35, 523, 10.1007/s00259-007-0679-8
2011, Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme, Arch Pathol Lab Med, 135, 1486, 10.5858/arpa.2010-0740-OA
2016, Ga-68-PSMA PET/CT imaging in primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 43, 795, 10.1007/s00259-015-3297-x
2017, Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas, Clin Nucl Med, 42, e433, 10.1097/RLU.0000000000001769
2018, Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy, Eur J Nucl Med Mol Imaging, 45, 886, 10.1007/s00259-018-3934-2
2017, Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis, Clin Nucl Med, 42, e41, 10.1097/RLU.0000000000001451
2018, Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody, J Neurooncol, 138, 581, 10.1007/s11060-018-2825-5
2018, Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study, Clin Nucl Med, 43, e304, 10.1097/RLU.0000000000002175
2019, 18F-PSMA 1007 brain PET/CT imaging in glioma recurrence, Clin Nucl Med
2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, 10, 459, 10.1016/S1470-2045(09)70025-7
2014, Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases, Cancer Cell Int, 14, 26, 10.1186/1475-2867-14-26
2014, (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma, Eur J Nucl Med Mol Imaging, 41, 1461, 10.1007/s00259-014-2766-y
2018, Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade, Iran J Pathol, 13, 45, 10.30699/ijp.13.1.45
2012, Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis, J Nucl Med, 53, 207, 10.2967/jnumed.111.096859
2004, Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma, Eur J Nucl Med Mol Imaging, 31, 1464, 10.1007/s00259-004-1590-1
2019, Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the Revised Glioma WHO Classification 2016, Clin Nucl Med, 44, 214, 10.1097/RLU.0000000000002398
2007, FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumor grading, Eur J Nucl Med Mol Imaging, 34, 1933, 10.1007/s00259-007-0534-y
2019, Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients, Clin Nucl Med, 44, e318, 10.1097/RLU.0000000000002520